Angiogenesis pathway receptors

Angiogenesis pathway receptors are a group of cell surface proteins that regulate the formation of new blood vessels, a process known as angiogenesis. This group primarily includes the Vascular Endothelial Growth Factor Receptors (VEGFR-1, -2, and -3), Platelet-Derived Growth Factor Receptors (PDGFR), and Fibroblast Growth Factor Receptors (FGFR) (Ferrara & Adamis, 2016). These receptors are predominantly receptor tyrosine kinases that, upon activation by their respective ligands, trigger signaling cascades such as the PI3K/Akt and Ras/MAPK pathways to promote endothelial cell proliferation and migration (Lemmon & Schlessinger, 2010). While essential for physiological processes like wound healing and embryonic development, overactive signaling through these receptors is a hallmark of tumor growth and neovascular eye diseases (Carmeliet & Jain, 2011). Therapeutic intervention typically involves small-molecule inhibitors that block the ATP-binding site of the kinase domain or monoclonal antibodies that sequester ligands or block the receptor's extracellular domain. Common drugs in this class include ramucirumab and sunitinib, which are used extensively in oncology to inhibit tumor vascularization. However, targeting these receptors can lead to systemic side effects such as hypertension and impaired wound healing due to their roles in normal vascular homeostasis (Chen & Cleck, 2009).

Other names

Angiogenic receptorsPro-angiogenic receptorsVascular growth factor receptorsVEGF/PDGF/FGF receptors

Drugs targeting these receptors primarily function by inhibiting the intracellular tyrosine kinase domain (small-molecule TKIs) or by preventing ligand-receptor interaction through monoclonal antibodies or decoy receptors (Carmeliet & Jain, 2011). These actions block downstream signaling pathways like MAPK and PI3K, leading to reduced endothelial cell survival and vessel regression (Lemmon & Schlessinger, 2010).